Term ended Feb 18, 2024 · Medium confidence
20-year base term ended Feb 18, 2024
Why Medium: A parent in the chain could not be resolved.
USPTO later recorded it as expired for non-payment on Dec 2, 2024.
Feb 18, 2004
Feb 18, 2024
Oct 30, 2012
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 18, 2004, when application PCT/US2004/004646, the earliest non-provisional in its chain, was filed (this one was filed Nov 4, 2011); a parent in its chain could not be resolved (the next row) | Feb 18, 2024 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,767,851, US 8,093,423) | resolves to Feb 18, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| USPTO status record | Recorded as expired for non-payment on Dec 2, 2024, after the term ended | no change | High confidence |
| Computed term end | The steps above, in order | Feb 18, 2024 | Medium confidence |
This family
| Application PCT/US2004/004646 | PCT application no patent term | no patent term |
| US 7,767,851 | Term ended Feb 2024 | Feb 2024 |
| US 8,093,423 | In force Oct 2028 | Oct 2028 |
| US 8,338,642 | Term ended Feb 2024 | Feb 2024 |
| US 8,299,298 | this patent Feb 2024 | Feb 2024 |
| US 8,754,257 | Term ended Feb 2024 | Feb 2024 |
| US 8,609,896 | Term ended Feb 2024 | Feb 2024 |
| US 8,754,258 | Term ended Feb 2024 | Feb 2024 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 6, 2012 Reel 29417, frame 254 | Chan, Keith; Town, Winston | Globoasia, LLC | Assignment of Assignor's Interest |
| Dec 6, 2012 Reel 29417, frame 373 | Globoasia, LLC | Panion & BF Biotech, Inc. | Assignment of Assignor's Interest |
| Dec 10, 2012 Reel 29436, frame 54 | Globoasia, LLC | Panion & BF Biotech, Inc. | Corrective Assignment to Correct the Conveyance Type Previously Recorded on Reel 029417 Frame 0373. Assignor(S) Hereby Confirms the Nunc Pro Tunc Assignment with the Effective Date of August 18, 2006. |
| Apr 30, 2015 Reel 35540, frame 527 | Kwok, David W.k.; Stoynov, Nikolay Mintchev | Panion & BF Biotech Inc. | Assignment of Assignor's Interest |
| Apr 2, 2020 Reel 52295, frame 662 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Sep 2, 2020 Reel 53671, frame 221 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Second Amended and Restated Intellectual Property Security Agreement |
| Sep 10, 2020 Reel 54173, frame 451 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Third Amended and Restated Intellectual Property Security Agreement |
| Dec 17, 2020 Reel 54793, frame 455 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fourth Amended and Restated Intellectual Property Security Agreement |
| Mar 30, 2021 Reel 55776, frame 491 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifth Amended and Restated Intellectual Property Security Agreement |
| Jun 11, 2021 Reel 56544, frame 468 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Sixth Amended and Restated Intellectual Property Security Agreement |
| Sep 12, 2021 Reel 57474, frame 770 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Seventh Amended and Restated Intellectual Property Security Agreement |
| Dec 15, 2021 Reel 58399, frame 55 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Jun 16, 2022 Reel 60529, frame 168 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Tenth Amended and Restated Intellectual Property Security Agreement |
| Aug 22, 2022 Reel 61297, frame 238 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Eleventh Amended and Restated Intellectual Property Security Agreement |
| Nov 29, 2022 Reel 62012, frame 561 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Twelfth Amended and Restated Intellectual Property Security Agreement |
| Mar 29, 2023 Reel 63189, frame 65 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Thirteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 4, 2024 Reel 66205, frame 143 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 29, 2024 Reel 66377, frame 741 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 Reel 67839, frame 134 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 7,767,851, US 8,093,423, ends no earlier than this term, so it caps nothing.